drugset
drugset / Trial / NCT07099118

A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects

NCT07099118 ↗

Phase 1 Recruiting 96 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics study of HEC169584 capsules in healthy subjects .

Timeline

Start
2025-09-03
Primary completion
2026-12-30
Completion
2027-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC169584 Unknown 30 mg Oral
Subject HEC169584 Unknown 70 mg Oral
Subject HEC169584 Unknown 150 mg Oral
Subject HEC169584 Unknown 300 mg Oral
Subject HEC169584 Unknown 450 mg Oral
Subject HEC169584 Unknown 600 mg Oral
Subject HEC169584 Unknown 800 mg Oral

Indications

metabolic dysfunction-associated steatohepatitis